ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

As China and Canada feud, vaccine maker gains favor of both

CanSino will supply COVID-19 vaccine to Chinese military while running Canadian trials

CanSino Biologics claims to be the first to publish peer-reviewed data from a clinical trial of a COVID-19 vaccine.    © Reuters

DALIAN, China -- Racing to develop a vaccine for the novel coronavirus, Chinese biotechnology company CanSino Biologics has pulled off the feat of establishing warm ties with both China and Canada at a time of fraught relations between the two countries.

CanSino grabbed headlines in May when it said its vaccine generated neutralizing antibodies in first-phase trials -- claiming to be the first to publish peer-reviewed data from a clinical trial of a COVID-19 vaccine. Then the Tianjin-based company announced in late June that it had received the green light to supply the Chinese military. The Central Military Commission, which gave the go-ahead, apparently liked the vaccine enough even while it was still in development.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more